Medical
For the Majority of Advanced Malignancies, Combination Immunotherapy Offers No Additional Benefits, According to a Meta-Analysis
According to a recent Northwestern Medicine meta-analysis published in JAMA Oncology, nivolumab plus ipilimumab immunotherapy treatment was not associated with an improvement in survival for…